Drug intelligence / Profile preview

CTIX-1502

Development stage: Preclinical
Lead developer: Innovation Pharmaceuticals
Modality: Small Molecules
Administration: Oral, Topical, Systemic

Overview

**CTIX-1502** is an early-stage antifungal compound developed by Cellceutix (now likely rebranded or acquired). Preclinical laboratory research demonstrated activity against both systemic and localized Candida infections. In an oral candidiasis mouse model, it showed efficacy comparable or superior to nystatin, a commonly used topical antifungal agent. The company planned GMP manufacturing and a broad Phase 1 trial to evaluate indications including topical and systemic fungal infections, particularly Candida-related.

Beyond the preview

Go deeper on CTIX-1502.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTIX-1502.

Explore the full profile